# Scholarly Search Results

**Query:** NICE technology appraisal semaglutide obesity TA972 pdf

**Saved:** 2025-10-24T07:39:46.306400+00:00

---

A Google search for 'NICE technology appraisal semaglutide obesity TA972 pdf' found 10 results:

## Web Results
1. [critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875](https://www.semanticscholar.org/paper/ae13b6b91785191883cdf3ac70f6a3207d6edf15)
Date published: 2024
Source: Semantic Scholar

Wegovy®, semaglutide 2.4 mg, is a glucagon-like peptide-1 analogue that has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with obesity in the National Health Service (NHS). In this review, we provide a reflection on NICE TA875 and its implementation in the NHS.

2. [Subscriptions](https://www.semanticscholar.org/paper/3f3db414dea6203a0929c12842991d83a76c86d6)
Date published: 2008
Source: Semantic Scholar


3. [critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875](https://www.bjd-abcd.com/index.php/bjd/article/download/1183/1497)
Date published: 2024
Source: Crossref

<jats:p>Wegovy®, semaglutide 2.4 mg, is a glucagon-like peptide-1 analogue that has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with obesity in the National Health Service (NHS). In this review, we provide a reflection on NICE TA875 and its implementation in the NHS.</jats:p>

4. [NICE recommends semaglutide for managing obesity](https://doi.org/10.1002/psb.0010096)
Date published: 2023
Source: Crossref


5. [NICE provisionally recommends semaglutide for patients with obesity](https://doi.org/10.1211/pj.2022.1.129302)
Date published: 2022
Source: Crossref


6. [NICE approves semaglutide for limited use in obesity](https://doi.org/10.1002/tre.0030141)
Date published: 2023
Source: Crossref


7. [Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664](https://bjd-abcd.com/index.php/bjd/article/viewFile/737/983)
Date published: 2021
Source: Crossref

<jats:p>Saxenda, Liraglutide 3.0 mg, is a glucagon-like peptide-1 (GLP-1) analogue that is licensed for the treatment of adults with overweight and obesity. In this commentary we review the NICE technology appraisal (TA664) on the use of Saxenda in the National Health Service (NHS) and its implication in clinical practice.</jats:p>

8. [Untitled](https://doi.org/10.35802/203351)
Date published: 2016
Source: Crossref


9. [Weight loss drug semaglutide will ‘soon’ be available to eligible patients, says NICE](https://doi.org/10.1211/pj.2023.1.177160)
Date published: 2023
Source: Crossref


10. [It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE](http://link.springer.com/content/pdf/10.1186/s40900-016-0018-y)
Date published: 2016
Source: Crossref

